Clinical Trials Browser

Phase 1/2 × Withdrawn × Paclitaxel × Clear all

NCT05312372 2026-02-17

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Phase 1/2 Withdrawn

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Phase 1/2 Withdrawn

GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT03197584 2025-02-21

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Phase 1/2 Withdrawn

Ovarian Neoplasms

NCT03361319 2020-11-24

N3

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT00547443 2019-01-10

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00022230 2015-05-05

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT02044601 2014-04-24

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00209612 2009-02-17

Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.

Phase 1/2 Withdrawn

Gastrointestinal

Stomach Neoplasms